TIGIT and breast cancer: An anti-TIGIT mouse mAb, called 13G6, was produced and used to block TIGIT activity in a CT26 colon cancer, 4T1 mammary cancer, or methylocholanthrene (MCA)-induced fibrocarcinoma mouse model [116,118,122].